ITCI launches $500M stock offering; Q1 CAPLYTA sales ~$144.8M; MDD Ph3 positive

Intra-Cellular Therapies, Inc.

Commenced underwritten public offering of $500M common stock; underwriters have 30-day option to purchase additional 15%.
Preliminary Q1 2024 CAPLYTA net product sales ~$144.8M; cash and equivalents ~$477M as of March 31, 2024.
Positive Phase 3 topline results for lumateperone 42 mg as adjunctive MDD therapy: MADRS reduction -4.9 pts vs placebo (p<0.0001, ES=0.61).
Secondary endpoint CGI-S also met (p<0.0001, ES=0.67); safety profile consistent with prior studies.
Expect to file sNDA for MDD in H2 2024; Study 502 topline results expected late Q2 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Intra-Cellular Therapies, Inc. reported for the three months ended March 31, 2024 results: revenue $144.8 million.

Period: for the three months ended March 31, 2024
Revenue: $144.8 million
Result: preliminary results

Exact text from the filing

While we have not finalized our financial results for the first quarter of 2024, we expect to report that, for the three months ended March 31, 2024, our CAPLYTA net product sales were approximately $144.8 million, and as of March 31, 2024, we had cash, cash equivalents, investment securities and restricted cash of approximately $477 million. These amounts are preliminary, unaudited and may change, were prepared by management and are based on the most current information available to management

View on SEC.gov

548 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-097845

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.